ABVC Biopharma Inc
ABVC
查看詳細走勢圖
2.190USD
+0.150+7.35%
收盤 12/19, 16:00（美東）報價延遲15分鐘
52.98M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+7.35%
5天
+3.79%
1月
-17.67%
6月
+19.02%
今年開始到現在
+271.19%
1年
+317.94%
查看詳細走勢圖
TradingKey ABVC Biopharma Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
ABVC Biopharma Inc當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名208/404位。機構持股佔比非常高，中期看，股價處於下降通道。近一個月，市場表現非常差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
ABVC Biopharma Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
0
分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
ABVC Biopharma Inc亮點
亮點風險
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
ABVC Biopharma Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
ABVC Biopharma Inc簡介
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
公司代碼ABVC
公司ABVC Biopharma Inc
CEOPatil (Uttam Yashwant)
網址https://abvcpharma.com/
常見問題
ABVC Biopharma Inc(ABVC)的當前股價是多少？
ABVC Biopharma Inc(ABVC)的當前股價是 2.190。
ABVC Biopharma Inc 的股票代碼是什麼？
ABVC Biopharma Inc的股票代碼是ABVC。
ABVC Biopharma Inc股票的52週最高點是多少？
ABVC Biopharma Inc股票的52週最高點是5.480。
ABVC Biopharma Inc股票的52週最低點是多少？
ABVC Biopharma Inc股票的52週最低點是0.400。
ABVC Biopharma Inc的市值是多少？
ABVC Biopharma Inc的市值是52.98M。
ABVC Biopharma Inc的淨利潤是多少？
ABVC Biopharma Inc的淨利潤為-4.90M。
現在ABVC Biopharma Inc(ABVC)的股票是買入、持有還是賣出？
根據分析師評級，ABVC Biopharma Inc(ABVC)的總體評級為--，目標價格為--。
ABVC Biopharma Inc(ABVC)股票的每股收益（EPS TTM）是多少
ABVC Biopharma Inc(ABVC)股票的每股收益（EPS TTM）是-0.280。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
